Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus versus sunitinib sequencing in metastatic renal cell carcinoma
NL-OMON36802Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of everolimus and sunitinib in renal cell carcinoma (RCC) and metastatic renal cell carcinoma (mRCC), sponsored by Novartis. Primary endpoint: Progression-free survival during or after first-line treatment. Started Apr 2010; status: active, not recruiting.
02
Drugs
everolimussunitinib
03
Conditions
renal cell carcinoma (RCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NL-OMON36802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36802.